Anne-sophie W. Moller
Helsinki, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models.
Journal: Molecular therapy oncolytics
Published: December 21, 2021
Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor.
Journal: Journal of medical virology
Published: September 21, 2019
TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial.
Journal: British journal of cancer
Published: May 09, 2019
Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma.
Journal: Journal of medical virology
Published: February 15, 2019
Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks.
Journal: International journal of molecular sciences
Published: December 20, 2018
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model.
Journal: Oncoimmunology
Published: June 27, 2018
Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401.
Journal: Cancer gene therapy
Published: May 07, 2018
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model.
Journal: Journal of medical virology
Published: March 29, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026